Earnings Routine +

BioSyent Releases Financial Results for First Quarter 2026

BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

By The Northwire Desk — AI Analysis May 14, 2026 · 18:00 RX · 14.43 BioSyent Inc.

Executive Summary

Q1 2026 total company sales surged 27% YoY to $13.9 million, driven by the newly acquired Oral Science Inc., which contributed $2.98 million in sales and $0.48 million in EBITDA during its first month (March) under ownership.
Core pharmaceutical sales (primarily FeraMAX® and Tibella®) grew only 1% to $10.8 million, while legacy insecticide sales fell 58%.
Reported EBITDA rose 14% to $3.64 million, but adjusted EBITDA (excluding one‑time acquisition costs) advanced 22% to $3.91 million. Adjusted net income after tax climbed 10% to $2.55 million, and adjusted diluted EPS increased to $0.22 from $0.20 a year ago.
Trailing twelve‑month (TTM) adjusted diluted EPS reached $0.83, up $0.16 from the prior year.
The company repurchased 100,000 shares for cancellation under its NCIB and paid a quarterly dividend of $0.055 (a 10% increase).
Cash and short‑term investments fell to $10.9 million (from $28.65 million at year‑end 2025) following the $22.5 million cash outlay for the Oral Science acquisition. Total equity stood at $45.0 million.

Material Impact

The results demonstrate that the Oral Science acquisition is immediately accretive and diversifies revenue streams, exactly as management projected in February 2026. However, the news contains no major surprises relative to the February 9 acquisition announcement or the March 19 Q4 2025 earnings.
Core pharmaceutical sales are flat, a potential concern, but the overall profit improvement and disciplined capital allocation (share buybacks, dividend lift) are positive.
Given that the acquisition’s contribution had already been priced in – the stock rallied from ~$12 in early February to a high of $15.80 – the Q1 release is more of a confirmation than a game‑changing catalyst.
As a result, the news qualifies as Routine – Positive: it is incremental, in line with expectations, and does not materially alter the investment thesis.

RX · Price

Company Overview

BioSyent is a Canadian specialty pharmaceutical and oral‑health company. Its legacy business revolves around two key brands: FeraMAX® (an oral iron supplement) and Tibella® (a tibolone product for menopausal symptoms). The 2024 international Tibella® asset acquisition added ex‑Canada sales.
In March 2026, BioSyent acquired Oral Science Inc., a distributor of dental hygiene and oral health products, expanding its reach into dental clinics and diversifying revenue away from retail/pharmacy channels.
The company is debt‑light, pays a regular growing dividend, and actively repurchases shares.

More from BioSyent Inc.